Fluoropyrimidines (5-fluorouracil and capecitabine) are antimetabolite drugs, widely used for the treatment of a variety of cancers, both in adjuvant and in metastatic setting. Although the most common toxicities of these drugs have been extensively studied, robust data and comprehensive characterization still lack concerning fluoropyrimidine-induced cardiotoxicity (FIC), an infrequent but potentially life-threatening toxicity. This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate. The role of alternative chemotherapeutic options, namely raltitrexed and TAS-102, is discussed, and, lastly, we overview the most promising future directions in the research on FIC and development of diagnostic tools, including microRNA technology.

Fluoropyrimidine-induced cardiotoxicity

Depetris, Ilaria;Marino, Donatella;Cagnazzo, Celeste;Filippi, Roberto;Aglietta, Massimo;Leone, Francesco
Last
2018-01-01

Abstract

Fluoropyrimidines (5-fluorouracil and capecitabine) are antimetabolite drugs, widely used for the treatment of a variety of cancers, both in adjuvant and in metastatic setting. Although the most common toxicities of these drugs have been extensively studied, robust data and comprehensive characterization still lack concerning fluoropyrimidine-induced cardiotoxicity (FIC), an infrequent but potentially life-threatening toxicity. This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate. The role of alternative chemotherapeutic options, namely raltitrexed and TAS-102, is discussed, and, lastly, we overview the most promising future directions in the research on FIC and development of diagnostic tools, including microRNA technology.
2018
124
Apr
1
10
5-Fluorouracil; Capecitabine; Cardiac toxicity; Cardiotoxicity; FIC; Fluoropyrimidines; Uridine triacetate; Vistogard(®)
Depetris, Ilaria; Marino, Donatella; Bonzano, Alessandro; Cagnazzo, Celeste; Filippi, Roberto; Aglietta, Massimo; Leone, Francesco
File in questo prodotto:
File Dimensione Formato  
pdf.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 445.67 kB
Formato Adobe PDF
445.67 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1663850
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 45
social impact